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Abstract
We established a canine hemangiosarcoma cell line
derived from malignant endothelial cells comprising a
spontaneous tumor in a dog to provide a renewable
source of endothelial cells for studies of angiogenesis
in malignancy. Pieces of the hemangiosarcoma biopsy
were engrafted subcutaneously in a bg/nu/XID mouse
allowing the tumor cells to expand in vivo. A cell line,
SB-HSA, was derived from the xenograft. SB-HSA cells
expressed vascular endothelial growth factor (VEGF)
receptors 1 and 2, CD31, CD146, and avb3 integrin, and
produced several growth factors and cytokines, in-
cluding VEGF, basic fibroblast growth factor, and in-
terleukin (IL)-8 that are stimulatory to endothelial cell
growth. These results indicated that the cells recapitu-
lated features of mitotically activated endothelia.
In vivo, SB-HSA cells stimulated robust angiogenic
responses in mice and formed tumor masses com-
posed of aberrant vascular channels in immunocom-
promised mice providing novel opportunities for
investigating the effectiveness of antiangiogenic
agents. Using this model, we determined that IL-12,
a cytokine with both immunostimulatory and antian-
giogenic effects, suppressed angiogenesis induced
by, and tumor growth of, SB-HSA cells. The endothe-
lial cell model we have described offers unique
opportunities to pursue further investigations with
IL-12, as well as other antiangiogenic approaches
in cancer therapy.
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Introduction
Angiogenesis, the formation of new blood vessels from pre-
existing vessels, has been intensively studied over the past
several decades because of its fundamental importance in
tissue development, vascular diseases, and cancer. Angio-
genesis is most active during fetal development, whereas
after birth, it is an important physiological function in the
ovary and placenta, and in wound healing. Pathological angio-
genesis that is inappropriate and unregulated is a prominent
feature of malignancy that facilitates tumor growth and metas-
tasis. Improved treatment of malignancies that have pro-
gressed to the proangiogenic phenotype requires relevant
models to test the safety and efficacy of innovative antiangio-
genic therapies. Systems to study angiogenesis in the labora-
tory are limited by the transient nature of angiogenic events and
limited accessibility to angiogenic tissues. Sources of endothe-
lial cells currently used in the laboratory include human umbil-
ical vein, and bovine aorta, pulmonary vein, and pulmonary
artery [1–3]. A malignant hemangioendothelioma of murine
origin is also used for studying endothelial cell biology [4]. Other
endothelial cells, such as those derived from bovine adrenal
cortex and retina, rat brain, mouse aorta, epididymal fat pad,
thoracic duct, or liver, have been more difficult to maintain in
stable long-term culture [5–7]. In addition, several human
endothelial cell lines have been immortalized by transfection
or retroviral transduction with the human telomerase reverse
transcriptase gene (reviewed in Bouis et al. [8]).
In order to understand the developmental processes and
functions of normal cells, neoplastic cells have been used
because tumor cells are capable of proliferating both in vitro
and in vivo and, at the same time, can maintain many of the
properties of their normal counterparts. For example, plasma-
cytomas have provided material that has led to the character-
ization of Ig structure, and studies of teratomas have helped to
clarify how differentiation takes place [4]. In the same way,
endothelial cells derived from tumors or endothelial cell tumors
can be used to understand the biology of endothelial cells.
There is a potential advantage to a renewable source of
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endothelial cells for study because primary endothelial cells
have a limited lifespan and display characteristics that differ
from batch to batch due to their multidonor origin [8]. We
established a canine hemangiosarcoma cell line derived
from malignant endothelial cells comprising a spontaneous
subcutaneous tumor in a dog. These cells possess charac-
teristics typical of the endothelium, including surface expres-
sion of vascular endothelial growth factor (VEGF) receptors
1 and 2, CD31, CD146, avb3 integrin, and others, and
produce several factors including VEGF, basic fibroblast
growth factor (bFGF), and interleukin (IL)-8 that are stimula-
tory to endothelial cell growth. In vivo, the cells stimulate
robust angiogenic responses in mice and form tumor masses
composed of aberrant vascular channels in immunocompro-
mised mice, providing excellent opportunities for investigat-
ing the effectiveness of antiangiogenic agents.
Using this model, we determined that IL-12, a cytokine
with both immunostimulatory and antiangiogenic effects,
suppressed both tumor-associated angiogenesis and growth
of canine hemangiosarcoma in vivo. Tumor growth delay of
the malignant endothelial cells may have been due to sup-
pression of tumor-induced neovascularization by IL-12, di-
rect suppression of malignant endothelial hemangiosarcoma
cell growth by IL-12, activation of tumoricidal NK cells, or a
combination of mechanisms. Taken together, these studies
report a valuable new model for investigating angiogenesis
and demonstrate a promising role for IL-12 in controlling the
growth of angiogenic tumors.
Materials and Methods
Source of Malignant Endothelial Cells
A 9-year–old German shepherd dog presented to the
Veterinary Medical Teaching Hospital (VMTH) at the Univer-
sity of Wisconsin School of Veterinary Medicine (UW-SVM)
was euthanized for an enlarging 20-cm fluctuant subcutane-
ous mass over the left shoulder. The mass had previously
been biopsied and diagnosed as a hemangiosarcoma, a
malignancy of endothelial cells, by a board-certified veteri-
nary pathologist. Immediately following euthanasia, a small
piece of tumor was excised and used as the source of tissue
to develop the current studies. All procedures were per-
formed in accordance with a protocol approved by the Animal
Care and Use Committee of the UW-SVM.
Mice
BALB/c and NOD-SCID mice were purchased from
Jackson Laboratories (Bar Harbor, ME) and bg/nu/XID mice
were purchased from Harlan (Indianapolis, IN). BALB/c and
NOD-SCID mice were subsequently bred in a colony at the
UW-SVM. The bg/nu/XID mice were used in experiments
following receipt from the vendor. All mice were 8 to 12
weeks old when used in experiments.
Development of SB-HSA Malignant Endothelial Cell Line
Several small pieces (< 0.5 cm diameter) of the heman-
giosarcoma biopsy were engrafted subcutaneously in the
dorsal cervical area of a bg/nu/XID mouse. The mouse was
anesthesized with intraperitoneal injection of avertin (tribro-
moethanol/tertiary amyl alcohol [1:1] diluted to 2% in 10%
ethyl alcohol, 0.1 ml/10 g of body weight). The fur was
clipped and the skin cleansed with 70% ethanol. A small
skin incision was made and a subcutaneous pocket was
created by blunt dissection. Tumor pieces washed in phos-
phate-buffered saline (PBS) were introduced into the pocket
and the skin wound closed. Following recovery, the mouse
was monitored for 120 days, at which time a 1-cm-diameter
tumor was present and the animal was sacrificed. The tumor
was excised and a portion was snap-frozen with liquid
nitrogen in Tissue Tek OCT compound (Sakura Finetek
USA, Torrance, CA) for immunohistochemical staining and
the remainder was used for establishing a primary canine
hemangiosarcoma cell line. The tumor tissue was minced
and transferred to a flask containing a modified enzyme
dissociation solution and glass beads, as described [9].
The enzyme dissociation solution consisted of 270 U/ml type
I collagenase (Invitrogen Life Technologies, Baltimore, MD),
200 U/ml DNAse from bovine pancreas (Sigma, Indianapolis,
IN), and penicillin–streptomycin (10,000 IU/ml penicillin and
10 mg/ml streptomycin) solution 1% vol/vol (Mediatech, Inc.,
Cellgro, Herndon, VA) dissolved in Minimal Essential Medi-
um Eagle with Earle’s balanced salt solution (BioWhittaker,
Walkersville, MD). Tissue pieces were incubated at 37jC in a
5% humidified CO2 atmosphere with gentle agitation using a
magnetic stirrer. After approximately 1 hour, the suspension
was allowed to stand for a few minutes in order for the larger
undissociated pieces to settle. The top suspension was
collected and passed through a 40-mm nylon mesh cell
strainer and centrifuged at 400g for 8 to 10 minutes. The
cell pellet was washed with PBS depleted of Mg and Ca
(dPBS) and centrifuged at 400g for 8 to 10 minutes. Red
blood cells were lysed with an ammonium chloride lysing
buffer and the wash step was repeated. The cell pellet was
resuspended in RPMI 1640 medium supplemented with 10%
heat-inactivated fetal bovine serum, 1% vol/vol penicillin–
streptomycin solution, 2 mM sodium pyruvate, 2 mM
L-glutamine, and 10 mM HEPES buffer (Sigma-Aldrich,
St. Louis, MO); transferred to a 75-cm2 tissue culture flask;
and incubated overnight at 37jC in a humidified 5% CO2
atmosphere. At that time, the medium was aspirated and the
adherent cells were gently washed with PBS before endo-
thelial growth medium (EGM-2; BioWhittaker) was added to
the flask. The cells were expanded in EGM-2 medium and
passaged when confluent.
After 14 passages, the cells were sorted by direct two-
color immunofluorescence labeling (described in Flow
Cytometry section). The brightest 10% of the cells labeling
positive for expression of avb3 integrin and CD146 were
collected, cultured in EGM-2 medium, and expanded. When
sufficient cell numbers were available, 5  106 cells were
injected subcutaneously into the dorsum of a bg/nu/XID
mouse and allowed to grow until a 1-cm3 tumor developed
after 30 days. The mouse was euthanized and the tumor
was excised. Once again, a portion was snap-frozen in
OCT compound for immunohistochemical staining and the
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remaining tumor was used to establish a single-cell sus-
pension using the method described above, then sorted a
second time for bright staining of avb3 integrin and CD146.
The brightest cells were collected and plated in 75-cm2
flasks in EGM-2 medium for expansion. These cells, called
the SB-HSA cell line developed from the second passage
in a bg/nu/XID mouse, were used for all experiments
(Figure 1). Aliquots of early passages were frozen in liquid
nitrogen.
Flow Cytometry
Cell sorting and flow cytometric analysis of the SB-HSA
cell line were done by direct two-color immunofluorescence
labeling using a FACSCalibur cell sorter or a FACScan flow
cytometer (Becton Dickinson, San Jose, CA). For cell sorting
and flow cytometry, fluorescein isothiocyanate (FITC)– or
phycoerythrin (PE)–conjugated monoclonal antibodies
(mAbs) specific for two endothelial cell surface antigens
were used. Murine mAb P1H12 (IgG1; Chemicon Interna-
tional, Temecula, CA) that recognizes CD146, an endothelial
surface antigen [10], was conjugated to FITC, and mAb
LM609 (murine IgG1; Chemicon), which recognizes avb3
integrin (CD51/CD61) in numerous species [11–18], includ-
ing the dog but not the mouse (Chemicon LM609 Datasheet
and confirmed in our laboratory), was conjugated to PE.
Briefly, SB-HSA cells were washed with HBSS and de-
tached with 5 mM EDTA. Cells were then collected with
EGM-2 medium and centrifuged at 400g for 5 minutes. The
cell pellet was washed with dPBS and centrifuged at 400g
for 5 minutes. The washed cells were resuspended in 1 ml
of dPBS and counted using a hemocytometer. Cells were
further diluted with cold dPBS containing 1% bovine serum
albumin (BSA) and adjusted to a concentration of 5  106/ml,
and 50 ml (2.5  105 cells) was placed into microcentrifuge
tubes for staining. mAbs (5 mg/ml) were added to individual
tubes and the cells were incubated at 4jC in the dark for
30 minutes, then washed with cold dPBS containing 1%
BSA. FITC- or PE-conjugated irrelevant mouse IgG1 anti-
bodies (3 ml/2  105 cells) were used as isotype controls.
Propidium iodide was added just before cell analysis as a
live–dead discriminator. Ten thousand events were collect-
ed and analyzed with the CellQuest v.3.3 software package
(Becton Dickinson). Additional antibodies used in flow cytom-
etry experiments included rat antimouse c-kit (CD117; Phar-
mingen, San Diego, CA) conjugated to PE and an irrelevant
rat antimouse IgG2b conjugated to PE as its control.
SB-HSA Tumor Xenograft
Canine hemangiosarcoma xenografts were established
in NOD-SCID mice by injection of 5  106 SB-HSA cells
Figure 1. Establishment of a canine hemangiosarcoma (HSA) xenograft model. A biopsy was taken from a subcutaneous HSA of the right shoulder of a 9-year–old
German shepherd dog. Several small pieces of the HSA biopsy were engrafted subcutaneously in the dorsal cervical area of a bg/nu/XID mouse and the skin
wound was sutured closed. The mouse was monitored for 120 days, at which time a 1-cm-diameter tumor was present and the animal was sacrificed. The tumor
was excised and a portion was snap-frozen with liquid nitrogen in OCT compound for immunohistochemical staining and the remainder was used for establishing
the primary canine HSA cell line. After 14 passages, the cells were sorted and cells labeling positive for expression of av 3 integrin (with a canine-selective antibody)
and CD146 (P1H12) were collected and expanded. About 5  10 6 cells were injected subcutaneously into the dorsum of a second bg/nu/XID mouse and allowed
to grow for 30 days until a 1-cm3 tumor had developed. The tumor was then excised. A portion was snap-frozen in OCT compound for immunohistochemical
staining, and the remaining tumor was used to establish a single-cell suspension that was then expanded. These cells, called the SB-HSA cell line developed from
the second passage in a bg/nu/XID mouse, were used for the remainder of the experiments to induce tumors in NOD-SCID mice.
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suspended in 200 ml of PBS over the dorsum using a
26-gauge needle and tuberculin syringe.Micewere examined
every other day until tumors were detected and could be
measuredwith calipers. Animalswere sacrificedwhen tumors
reached a size of 1 cm3. In some experiments, 5  106
SB-HSA cells were injected intravenously into the tail vein.
Pathology
Gross and histopathological examinations of tissues from
experimental mice were performed by a board-certified veter-
inary pathologist (H.S.). For histological examination, routine
hematoxylin and eosin staining of fixed sections was done.
Immunohistochemistry
Immunohistochemical staining was performed on fresh
frozen and formalin-fixed paraffin-embedded sections from
SB-HSA tumors obtained from bg/nu/XID and NOD-SCID
mice. Antibody clone P1H12 (anti-CD146; Chemicon) and
LM609 (anti–avb3 integrin [CD51/CD61]; Chemicon) were
used on fresh frozen sections, whereas mouse anti–human
PECAM-1 (anti-CD31, clone JC/70A; Dako, Carpinteria, CA)
and rabbit anti–human factor VIII polyclonal antibody (von
Willebrand’s factor; Signet, Dedham, MA) were used on fixed
tissue sections following antigen retrieval. The final product
was developed using alkaline phosphatase with New Fuch-
sin as the chromogen (Histo-Mark Red kit; Kirkegaard and
Perry Laboratories, Gaithersburg, MD), as described [19,20].
Immunohistochemistry was performed by IHC Services
(Smithville, TX; J. Wojcieszyn, PhD).
Fluorescence In Situ Hybridization (FISH)
FISH—using a panel of canine bacterial artificial chromo-
some (BAC) clones representing single-locus probes for
chromosomes X, Y, and 26, and a BAC clone representing
the canine tumor-suppressor gene PTEN—was employed to
confirm the genetic identity of SB-HSA cells. Probe labeling,
FISH, and image acquisition were performed as previously
described [21]. Briefly, chromosome preparations were gen-
erated from the cell line when the cells were f70% conflu-
ent. A conventional approach of colcemid arrest followed by
hypotonic (75 mM KCl) and fixation (3:1 methanol:glacial
acetic acid) treatments was used.
Reverse Transcription Polymerase Chain
Reaction (RT-PCR)
Total RNA was extracted from SB-HSA cells with TRIzol
reagent (Invitrogen Life Technologies) and reverse transcrip-
tion was performed using SuperScript First Strand Synthesis
Systems for RT-PCR (Invitrogen Life Technologies) accord-
ing to the manufacturer’s instructions. The PCR products
were separated using a 1% agarose gel, stained with ethi-
dium bromide, and visualized with ultraviolet (UV) light.
Conditions used to detect messages of interest in endothelial
cells are shown in Table 1.
Corneal Angiogenesis Assay
Polyvinyl sponges (Rippey, Eldorado Hills, CA) preirradi-
ated with 2000 Gy of gamma irradiation (cesium source)
were cut into 4  4  2 mm pieces, and 70,000 SB-HSA
Table 1. RT-PCR Conditions
cDNA Primers* (Forward: 5V–3V; Reverse: 5V–3V) Thermal Cycler
Programy
PCR Product
(bp)
VEGF CCATGAACTTTCTGCTCTCTTGTTG
TCTTGCTCTATCTTTCTT
95jC, 1 min; 60jC,
1 min; 72jC, 1 min
450
VEGFR-1 (flt) AAGCAGCCCATTCATGGTCTTTGCCCA
TCAGGGATCAGGGTATCAAG
95jC, 1 min; 58jC,
1 min; 72jC, 1 min
380
VEGFR-2 (flk) ACTGGAGCCTACAAGTGCTTCTAC/TTC/TT
TCTTGGTCATCAGC/TCCACTG
95jC, 1 min; 59jC,
30 sec; 72jC, 1 min
650
bFGF CTTCAAGGACCCCAGCGGCGCTCTT
AGCAGACTTGG
94jC, 30 sec; 55jC,
30 sec; 72jC, 1 min
400
IL-8 TCAGAACTTCGATGCCAGTTTCAC
GGATCTTGTTTCTC
94jC, 1 min; 52jC,
1 min; 72jC, 1 min
227
MMP-2 CCGTATGAGATCAAGCAGATTTACGG
GTCCTCAATATCGAG
94jC, 30 sec; 56jC,
30 sec; 72jC, 30 sec
450
MMP-13 ATCTGTATGAGGAAGACTGACCAGAAG
GTCCATCAA
94jC, 30 sec; 53jC,
30 sec; 72jC, 30 sec
450
SCF CCAGAGTCAGTGTCACAAAACCCTTCTT
CCAGTATAAGGCTCC
94jC, 1 min; 58.5jC,
1 min; 72jC, 1 min
196
c-Kit CACCCTGGTCATTACAGAATATTGCGG
AAGCCTTCCTTGATCATCTTG
95jC, 30 sec; 58jC,
30 sec; 72jC, 30 sec
650
-Actin CATGTTTGAGACATTCAACACCCCGCC
ATCTCTTGCTCGAAGTCCAG
95jC, 1 min; 50jC,
1 min; 72jC, 1 min
325
*All primers were canine-specific sequence except -actin, which was a human-specific sequence.
yThirty-five cycles were used for all amplifications except -actin cDNA, which was amplified by 30 cycles. All conditions used a 95jC to 96jC 2-minute hot start
with the exception of c-kit and -actin. A final 7-minute extension at 72jC was used for all conditions, after which samples were held at 4jC. The concentration of
MgCl2 was 1.5 mM in all conditions except VEGF, IL-8, and c-kit, where it was 3 mM. VEGFR-1 was cloned in our laboratory (GenBank accession no. AF262963).
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cells were introduced into the sponges. BALB/c mice were
anesthesized with Avertin and a small surgical micropocket
was created in the center of the avascular cornea. Sponges
were then inserted into the micropocket. Eyes were exam-
ined for neovascularization daily using an ophthalmic micro-
scope (Carl Zeiss, Inc., Thornwood, NY). On day 14 after
implantation, 200 ml of FITC-conjugated high-molecular-
weight dextran (2,500,000 Mw, 200:1; Sigma) (FITC–dex-
tran) was injected into the tail vein, and the animal was
sacrificed 5 minutes later. The eyeball was enucleated from
the orbital cavity and fixed for 5 minutes in 4% paraformal-
dehyde. The cornea with the adjacent limbus was dissected,
rinsed in PBS, and mounted on a glass slide in 10% glycerol.
Phase contrast and fluorescence microscopy were used to
visualize the general layout of the cornea and the presence
of perfused blood vessels, respectively [22,23]. A computer
program (Powerpoint; Microsoft, Redmond, WA) was used
to quantitate the percentage of the image containing fluoro-
chrome-labeled vessels through comparison of pixel counts
above background.
Subcutaneous Matrigel/Sponge Assay
A sponge/Matrigel assay was used to visualize the an-
giogenic reaction induced by SB-HSA cells in the subcuta-
neous microenvironment, as described [24]. Matrigel (500 ml,
500:1; BD Biosciences, Bedford, MA) was injected subcuta-
neously with a 27-gauge needle in the flank region of 2.5- to
3.5-month–old BALB/c mice and allowed to solidify for 30 to
60 minutes. At that time, mice were anesthesized with
Avertin given intraperitoneally. The fur overlying the Matrigel
plug was clipped, the skin cleansed with betadine, and a stab
incision was made over the Matrigel bleb. A stab incision was
then made directly into the Matrigel plug and a sterilized
polyvinyl sponge (3  2  1.5 mm) containing 1  105 SB-
HSA tumor cells was introduced through the nick in the
Matrigel and advanced to the center of the plug with a thumb
forceps. The skin wound was closed with a 6-0 nylon suture
and the mouse recovered under a heat lamp. Mice were
observed after 24 hours to monitor the condition of
the wound.
After 2 weeks, 200 ml of FITC–dextran was injected
through the tail vein. Mice were euthanized 3 to 5 minutes
later; the Matrigel plug was removed, separated from the
abdominal skin and muscle, and fixed in 10% formalin.
Phase contrast microscopy was used to examine the topog-
raphy of the Matrigel plug, and the perfused blood vessels
were visualized using fluorescence illumination.
Treatment of SB-HSA Tumor-Bearing Mice with IL-12
NOD-SCID mice were injected subcutaneously over the
dorsum with SB-HSA cells (5  106 cells/200 ml). Two days
later, they were anesthesized and osmotic pumps (Alzet
Corporation, Palo Alto, CA) containing 33.3 mg in 200 ml of
murine recombinant (mr) IL-12 (Peprotech, Rocky Hill, NJ) or
200 ml of PBS were inserted subcutaneously through a small
flank skin incision. The skin wound was closed with wound
clips. Pumps were designed to deliver 6 ml/day (1 mg/day
IL-12) for 4 weeks. The mice were examined every other day
for tumor development. Two perpendicular diameters were
measured with calipers and tumor volume was calculated
using the formula (Dd 2)p / 6, with D as the largest and d as
the smallest diameters.
Statistical Analyses
Comparisons between tumor size and angiogenic
responses of mice treated with IL-12 or PBS were made
using a two-sample Wilcoxon test. A P value V .05 was
considered significant.
Results
Flow Cytometry
Dissociated tumor cells obtained from the primary canine
hemangiosarcoma tumor explant in a NOD-SCID mouse
showed bright staining with mAb P1H12 (anti-CD146) and
LM609 (anti–avb3 integrin) (Figure 1). P1H12 recognizes an
antigen expressed chiefly by endothelial cells [10]. LM609
recognizes an adhesion molecule found on mitotically active
endothelial cells. Although the species specificity of LM609 is
broad, notably, it does not bind to avb3 integrin in the mouse.
Taken together, the staining pattern exhibited by the cells
derived from the primary tumor explant supports an endo-
thelial nonmurine cell type consistent with the canine heman-
giosarcoma transplanted to the first mouse. The brightest
10% of dually fluorescent cells (dot plot, upper right quad-
rant; Figure 1) were collected aseptically and expanded in
culture to establish the SB-HSA cell line, as described in
Materials and Methods section. This cell line was then used
in the remainder of the experiments.
SB-HSA Tumor Xenograft
Cohorts (n = 2, 4, 6, 12) of NOD-SCID mice injected with
SB-HSA cells typically developed large (1 cm3) subcutane-
ous tumors 3 to 4 weeks after cells were injected (Figure 2).
When tumors reached this size, mice were euthanized in
accordance with animal use guidelines. Grossly, the tumors
formed expansile infiltrative masses that were adherent to,
and invading, the musculature deep to the subcutis. The
overlying skin was also adhered to the tumor. The tumors
were firm, lobulated, reddish/maroon masses that bled read-
ily on cut surface (Figure 2). The gross appearance of lungs
from these animals was considered to be normal. Mice (n = 3)
that received only intravenous injections of SB-HSA cells
through the tail vein were sacrificed after 2 months and found
to have multifocal maroon tumor nodules (5 mm diameter)
disseminated throughout the lungs (Figure 2) as well as an
occasional larger (1 cm) subcutaneous tumor.
Histopathology
The tumor tissue was comprised of clusters of small
sheets of pleiomorphic elongate plump spindle cells fre-
quently forming slit-like spaces, many of which contained
erythrocytes (Figure 3). The cells comprising these foci
were polygonal to spindle-shaped, with small amounts of
eosinophilic cytoplasm, usually indistinct cell margins, high
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nuclear-to-cytoplasmic ratios, with oval variably sized nuclei
with finely stippled chromatin, and variably sized multiple
nucleoli. There were two mitotic figures per high-power field.
The microscopic features were indistinguishable from ca-
nine hemangiosarcoma.
Immunohistochemistry
Immunohistochemical staining on fresh frozen and fixed
tumor tissue from NOD-SCID mice showed positive staining
of the tumor cells with antibodies P1H12 (anti-CD146),
PECAM-1 (anti-CD31), and factor VIII, confirming the endo-
thelial nature of the tumor (Figure 4). The cells also showed
specific staining with LM609 (anti–avb3 integrin).
FISH
FISH analysis of SB-HSA chromosome preparations from
cultured SB-HSA cells yielded hybridization signal for all of
the canine-specific probes tested, indicating that the chro-
mosomes were of canine origin (data not shown).
RT-PCR
RT-PCR was used to assess expression of message for
several endothelial cell growth factors, receptor tyrosine
kinases, and matrix metalloproteinases (MMPs) in SB-HSA
cells (Figure 5A). Using primers designed from canine
gene sequences, SB-HSA cells were found to express
message for proangiogenic proteins including VEGF, bFGF,
and IL-8. Message for receptor tyrosine kinases VEGFR-1
and VEGFR-2 and c-kit were also expressed as was the
message for stem cell factor (SCF), the ligand for c-kit.
Expression of c-kit has been associated with cells of the
endothelial lineage. SB-HSA cells also expressed message
Figure 2. SB-HSA cells produce tumors in immunodeficient mice. (A)
Injection of 5  106 SB-HSA cells subcutaneously into NOD-SCID mice
routinely produced large tumors within 3 to 4 weeks. Such a tumor has grown
on the dorsal midline of the mouse in this photo. Inset: The gross appearance
of SB-HSA tumors from NOD-SCID mice exhibits features indistinguishable
from hemangiosarcoma in the dog. There is a characteristic bright red/
maroon color to the tumor and the tumor bled excessively when cut. The
tumor was highly vascular. Although implanted in the subcutaneous tissue,
the tumors were invasive into the underlying musculature. (B) NOD-SCID
mice were injected intravenously with 70,000 SB-HSA cells through the tail
vein. After 2 months, mice were sacrificed and found to have multifocal
maroon tumor nodules (5 mm diameter) disseminated throughout the lungs.
This route of administration routinely produced pulmonary metastases.
Figure 3. SB-HSA tumors in NOD-SCID mice are histologically identical to
canine hemangiosarcoma. The histological appearance of SB-HSA tumors
grown in NOD-SCID mice, shown above, is indistinguishable from naturally
occurring hemangiosarcoma in the dog. At low ( 40) power (A), there are
sheets of tumor cells with blood-filled spaces and areas of necrosis (light pink,
lower right). At high ( 400) power (B), plump atypical endothelial cells (black
arrows) can be seen forming tortuous vascular spaces (white arrows).
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for MMP-2 andMMP-13. These results suggest that SB-HSA
hemangiosarcoma cells express proteins and receptors ca-
pable of stimulating endothelial cell growth and the ability for
SB-HSA cells to promote their own growth in an autocrine
and/or paracrine manner. In addition, MMP expression sug-
gests that the cells are capable of altering the extracellular
matrix, providing a mechanism for expansion and invasion.
Flow cytometry using an anti–c-kit antibody was positive,
demonstrating that protein was expressed for at least one of
the transcripts amplified by RT-PCR from SB-HSA cells
(Figure 5B).
Angiogenesis Assays
Two in vivo assays were used to assess the angiogenic
properties of SB-HSA cells. The rationale for performing
these experiments was based on the angiogenic profile
revealed for this cell line by RT-PCR, which predicted the
capacity of SB-HSA cells to stimulate new vessel growth.
Further, hemangiosarcoma, being a malignancy of endo-
thelial cells, is likely to be highly adapted to sustaining the
needs for endothelial cell growth. In the corneal angiogen-
esis assay, sponges containing SB-HSA cells implanted
onto the avascular cornea of BALB/c mice induced marked
neovascularization, with neovessels advancing from the
limbus toward the sponge (Figure 6A). Vessel ingrowth
was detectable by 2 days following placement of the
sponge, with vessels reaching the sponge by 12 days.
Vessels were large and tortuous, with numerous points of
arborization. Control corneas receiving sponge implants
but without SB-HSA cells did not show neovascularization.
In the subcutaneous sponge/Matrigel assay in BALB/c
mice, vascular invasion of the Matrigel plug arising from
the periphery and progressing centrally toward the sponge
was detectable after 1 week. By 2 weeks, there was
marked arborization of the infiltrating blood vessels that
formed a network surrounding the sponge containing the
SB-HSA cells (Figure 6B ). Control sponge/Matrigel
implants lacking these tumor cells failed to elicit a vascular
response. These results confirmed that SB-HSA cells are
strong inducers of angiogenesis.
Figure 4. Immunohistochemical staining confirms endothelial lineage of SB-HSA cells. Immunohistochemical staining was performed on fresh frozen and formalin-
fixed, paraffin-embedded sections from SB-HSA tumors obtained from bg/nu/XID and NOD-SCID mice. Anti – factor VIII polyclonal antibody (A and B) and anti-
CD31 (C and D) were used on fixed tissue sections following antigen retrieval, and P1H12 (E and F) was used on fresh frozen sections. The final product was
developed using alkaline phosphatase with New Fuchsin as the chromogen. Positive staining is appreciated as a red color. Expression of these markers supports
an endothelial lineage for the cells comprising the SB-HSA tumor. Original magnification, 40 (panels A, C, and E) and  100 (panels B, D, and F).
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IL-12 Suppresses Angiogenesis Induced by SB-HSA Cells
In Vivo
The corneal pocket angiogenesis assay was also used to
determine whether IL-12 could suppress angiogenesis in-
duced by SB-HSA cells. Cohorts (n = 5) of BALB/c mice were
randomized to receive either mrIL-12 (1 mg/day) or PBS.
Each was delivered as a continuous subcutaneous infusion
by osmotic pumps implanted subcutaneously 2 days after
sponges containing 70,000 SB-HSA cells were placed into
corneas as described above. After 1 week of treatment, mice
were injected with FITC–dextran and euthanized, and the
corneas were examined. Compared to the PBS-treated
control group (Figure 6C), IL-12–treated mice showed sig-
nificantly (P < .05) less corneal neovascularity (Figure 6D) as
evidenced by markedly reduced corneal fluorescence.
These results prove that IL-12 mediates a strong antiangio-
genic effect against malignant endothelial cells that are
capable of inducing robust neovascularization.
IL-12 Suppresses Growth of SB-HSA Tumors In Vivo
IL-12 is a cytokine with pleiotropic effects, including
suppression of angiogenesis due to in vivo inhibition of
endothelial cell growth. This activity is mediated by down-
stream chemokines such as IP-10 and Mig, which are
induced by interferon-g in response to IL-12. We evaluated
the capacity of IL-12 to suppress the growth of SB-HSA
tumors in NOD-SCID mice and, in so doing, explored the
potential to use the inhibition of SB-HSA tumor development
as a surrogate marker for suppression of endothelial cell
growth and angiogenesis. Control mice that were injected
subcutaneously with SB-HSA cells and received PBS devel-
oped tumors at the site of cell inoculation by the second
week, which progressively enlarged over the 4-week obser-
vation period (Figure 7). In contrast, the growth of tumors in
mice that received the continuous subcutaneous infusion of
IL-12 was initially suppressed for 2 weeks followed by slower
growth and significantly (P = .016) smaller size by the end of
the 4-week observation period (Figure 7).
Discussion
We successfully established a transplantable endothelial
tumor in mice derived from a spontaneous endothelial ma-
lignancy in a dog. When injected subcutaneously, cultured
cells derived from the canine tumor repeatedly produced
locally invasive endothelial cell tumors in mice. Intravenous
injection of cells into the tail vein resulted in growth of
disseminated tumor nodules throughout the lungs and other
sites. The pattern of immunohistochemical antibody reactiv-
ity confirmed tumors to be endothelial and not derived from
murine tissues, whereas FISH analyses further validated the
cells to be of canine origin. Identification of growth factors
and receptors potentially important for mediating autocrine
and paracrine cell growth helped to shed light on putative
growth pathways important for the survival of SB-HSA cells.
Moreover, the array of receptors we investigated by RT-PCR
is consistent with pathways known to be important to endo-
thelial cell growth. Thus, the endothelial model we have
described has the potential for studying angiogenesis as
well as for investigating strategies to modulate angiogenesis
in cancer. Although in vivo angiogenesis assays are time-
consuming and more complicated than in vitro assays, they
are essential because they preserve the complexities of
angiogenesis that no in vitro system can duplicate [25].
Given the relative paucity of endothelial cell models available
for studying angiogenesis, the system we have described
has unique merits in this field. Inhibition of SB-HSA cell
growth and metastasis by potential antiangiogenic agents
can be useful to assess the activity of these compounds. It
must be kept in mind, however, that the underlying cells in
this model are malignant and may therefore differ from the
normal endothelial cells from which they arose. In this
respect, they exhibit characteristics that may be common
to normal endothelial cells, while at the same time exhibiting
features that deviate from the normal characteristics of the
nontransformed endothelial parent cells.
This endothelial model was developed from a canine
hemangiosarcoma. Hemangiosarcoma arises from trans-
formed vascular endothelial (blood vessel) cells [26]. This
tumor represents 7% of all canine malignancies, and it is
more commonly seen in male dogs between 8 and 10 years
old. German shepherd dogs are at greatest risk for heman-
giosarcoma, but Golden Retrievers, Great Danes, boxers,
English setters, and pointers are also overrepresented
Figure 5. Expression of endothelial growth factors and receptors by SB-HSA
cells. (A) RT-PCR was used to detect messenger RNA for endothelial cell
growth factors (VEGF, bFGF, and IL-8) and some of their receptors (VEGFR-1
and VEGFR-2). Other molecules of interest included PTEN, MMPs (MMP-2
and MMP-13), and c-kit. Primers were designed using canine sequences and
b-actin was used as a control. Expression of VEGFR-1 and VEGFR-2 is
considered selective for cells of the endothelial lineage. (B) Flow cytometry
using an anti – c-kit antibody demonstrated bright expression of c-kit by SB-
HSA cells confirming that the protein was expressed for one of the transcripts
amplified by RT-PCR.
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breeds [27,28]. The spleen, right atrium, and subcutis are the
most common sites for primary hemangiosarcoma in dogs
[26]. Local infiltration and systemic metastases are the
common growth patterns [26,28]. Metastatic sites are wide-
spread, with the lung and liver being the most frequently
affected organs [26–28]. Splenic rupture results in tumor
implants throughout the abdomen [28]. Morbidity and mor-
tality are often due to acute internal hemorrhage secondary
to rupture of highly vascular blood-filled tumors [28]. Despite
surgery and intensive chemotherapy, the median survival
time for dogs diagnosed with hemangiosarcoma is little more
than 6 months [29,30].
Endothelial tumors have been described in humans,
although less commonly than in the dog. In comparison to
dogs, human angiosarcomas are rare and more commonly
present as cutaneous tumors arising on the face and scalp
[31,32]. Similar to the dog, however, their clinical course is
aggressive and lethal due to metastases.
We identified a number of growth factor pathways in SB-
HSA cells, some of which have generated keen interest as
potential sites for antiangiogenic therapeutic intervention in
Figure 6. SB-HSA cells are potent inducers of angiogenesis and IL-12 inhibits this effect. (A) A polyvinyl sponge containing 70,000 SB-HSA cells was placed into a
surgically created corneal pocket in a BALB/c mouse. After 12 days, a robust angiogenic response is visible in the cornea, with neovascularization arising from the
limbus and proceeding toward the sponge implant (white structure in the center of the cornea). Implanted sponges that did contain SB-HSA cells failed to provoke
an angiogenic response. Experiment shown is representative of eight mice, all exhibiting a similar response. (B) Matrigel, an artificial connective tissue matrix, was
injected subcutaneously in the flank of a BALB/c mouse. After solidifying, a nick was made into the Matrigel through a skin incision, and a polyvinyl sponge (arrow)
containing 5  10 6 SB-HSA cells was inserted into the Matrigel. After 2 weeks and 3 to 5 minutes prior to sacrifice, 200 l of FITC–dextran was injected into the
tail vein and the Matrigel plug was removed. Under fluorescence microscopy, a pronounced angiogenic response was observed (arborized fluorescent green
vessels), which progressed toward the proliferating SB-HSA cells in the sponge. These experiments confirm the proangiogenic properties of SB-HSA cells. The
effect of IL-12 on SB-HSA– induced corneal angiogenesis was compared in BALB/c control mice given PBS (C) by continuous subcutaneous infusion versus
BALB/c that received 1 g/day mrIL-12 for 7 days by continuous subcutaneous infusion (D). Mice treated with IL-12 had significantly less corneal
neovascularization compared to the control mice (P < .05). Mice were injected with FITC–dextran just prior to euthanasia and corneal vessels were evaluated with
fluorescence microscopy. In this example, there was a 56% reduction in corneal neovascularization in the IL-12– treated mouse. The fluorescent vessel in the
ventral aspect of the cornea in (D) is the normal limbic vessel and the green squares in the centers of (C) and (D) are the SB-HSA sponges that have absorbed
fluorescein. Note that vessels have nearly reached the sponge in (C) whereas the cornea in (D) remains relatively avascular.
Figure 7. IL-12 suppresses growth of canine hemangiosarcoma. Cohorts
(n = 7) of NOD-SCID mice were injected subcutaneously with 5  10 6
SB-HSA cells over the dorsal thorax. Two days later, mice were anesthesized
and small osmotic pumps containing PBS or murine recombinant IL-12
(IL-12) were inserted subcutaneously in the mice from respective cohorts.
The pumps were designed to deliver continuous subcutaneous infusion of
6 l/day for 4 weeks. The mice in the IL-12 group each received 1 g/day
IL-12 during that time period. At the conclusion of the study, the pumps were
examined to verify that the contents had been delivered. Compared to the
control (PBS) group, tumors in the mice that received IL-12 were significantly
smaller (P = .016). Bars are standard errors.
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cancer. Therefore, the SB-HSA xenograft model may open
additional avenues for exploration of novel therapies to
inhibit angiogenesis. These could include blockade of the
VEGFR, a receptor of great importance to the growth and
development of endothelial cells, with tyrosine kinase inhib-
itors, anti–VEGFR antibody, or VEGFR immunization [33–
36]. The expression of c-kit by SB-HSA cells may also offer
an opportunity to pursue novel tyrosine kinase inhibitors that
have shown remarkable efficacy against several human and
canine cancers that express c-kit [37,38]. Likewise, the
adhesion molecule (avb3 integrin) we identified on SB-HSA
cells presents yet another potential target to study treat-
ments intended to disrupt its function such as the avb3
integrin–blocking antibody, LM609, or its human chimerized
form, Vitaxin, which is being evaluated in human clinical
trials [39,40].
We chose to investigate the ability of IL-12 to suppress
the growth of SB-HSA tumors. This question was of
interest for several reasons. IL-12 reportedly exerts anti-
angiogenic effects. This activity is mediated by several
chemokines (e.g., IP-10, Mig) that are induced in response
to interferon-g elicited by IL-12 [41,42]. In our system, we
wanted to evaluate the capacity of IL-12 to inhibit the
growth of an endothelial malignancy. We determined that
IL-12 significantly inhibited the growth of this tumor in
mice. The strain of mice used in these experiments
(NOD-SCID), although immunocompromised, possesses
NK cells that secrete interferon-g in response to IL-12
(data not shown). Others have also shown that SCID mice
maintain the ability to respond to IL-12 by increasing both
serum levels of IFN-g and IFN-g transcription in spleno-
cytes and that these responses are mediated by NK cells
[43]. We did not determine whether induction of antiangio-
genic chemokines by IL-12 suppressed growth of SB-HSA
tumors directly. It is possible that IL-12 augmented the
cytotoxic capacity of the NK cells, which, in turn, mediated
destruction of the xenografted tumor implants [44]. How-
ever, an investigation of the therapeutic effect of IL-12 on
mouse hemangiosarcomas determined that interferon-g,
and not cytotoxic lymphocytes, was responsible for sup-
pressing the proliferation of malignant murine endothelial
cells [45]. Still others have reported an effect of IL-12 on
promoting the apoptosis of endothelial cells [46]. Taken
together, these various possibilities may account for the
promise that IL-12 has shown as a treatment for aggres-
sive endothelial cell malignancies such as Kaposi sarcoma
[47]. Similarly, intralesional injection of IL-2 has been used
successfully as a treatment for cutaneous hemangiosar-
coma in humans [48–50]. Thus, there is active interest in
exploring a role for immunostimulatory cytokines in con-
trolling endothelial malignancies. Because of the numerous
potential mechanisms through which IL-12 can affect en-
dothelial cell growth, it is particularly interesting for this
purpose as well as for the suppression of endothelial cell
growth in other cancers. The endothelial cell model we
have described offers unique opportunities to pursue fur-
ther investigations with IL-12, as well as other antiangio-
genic approaches in cancer therapy.
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